Codexis sees $261,350 stock acquisition by Opaleye management

Opaleye Management Inc., an investment firm based in Boston, has acquired a significant number of shares in Codexis , Inc. (NASDAQ:CDXS), a company currently valued at $218.69 million. According to a recent SEC filing, Opaleye purchased 100,000 shares of Codexis common stock at a weighted average price of $2.6135 per share, totaling approximately $261,350. The acquisition comes as InvestingPro data shows the stock trading near its 52-week low of $2.47, with technical indicators suggesting oversold conditions. This transaction increases Opaleye’s holdings to 9,065,000 shares, which are held indirectly by Opaleye, L.P. The shares were acquired in multiple transactions, with prices ranging from $2.4784 to $2.71. Opaleye Management Inc. is a ten percent owner of Codexis, and the acquisition reflects its continued investment in the company. The stock has experienced significant volatility with a beta of 2.12, while maintaining strong liquidity with a current ratio of 4.18. InvestingPro analysis reveals 11 additional key insights about Codexis’s financial health and market position in their comprehensive Pro Research Report.

In other recent news, Codexis Inc. reported its fourth-quarter 2024 financial results, revealing a larger-than-expected loss per share and lower-than-anticipated revenue. The company announced an EPS of -$0.13, falling short of the forecasted -$0.04, alongside revenue of $21.5 million, which missed the expected $28.2 million. Despite the setbacks, Codexis continues to focus on expanding its enzymatic synthesis technology, particularly for siRNA production, with expectations for significant revenue increases in the second half of 2025. Additionally, Codexis has provided revenue guidance for 2025, anticipating a range of $64-68 million, which suggests double-digit growth. In other developments, Codexis disclosed the approval of equity grants for two new employees as part of its 2024 Inducement Plan, which aims to attract new talent. These equity grants include options to purchase shares and restricted stock units, designed to incentivize long-term service with the company. The company remains committed to its strategic initiatives, including securing a CDMO scale-up partner and exploring the construction of a kilogram-scale GMP facility to enhance production capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.